Company intelligence / Profile preview
Epsilogen
London, England, United Kingdomepsilogen.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
MOv18 IgE—the world’s first therapeutic anti-cancer immunoglobulin E antibody—has completed a phase I trial in folate receptor alpha-positive cancers with a favorable safety profile and early signs of clinical activity. The company’s pipeline now includes both clinical-stage and preclinical assets targeting solid tumors using novel engineered antibody formats that leverage the unique properties of multiple immunoglobulin classes.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)IgE antibodiesIgA antibodies (via TigaTx acquisition)Hybrid/engineered antibody formats combining IgE, IgA, and IgG functionalities
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Not explicitly listed, but investors include Novartis Venture Fund which may indicate strategic relationships.
Beyond the preview
Go deeper on Epsilogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epsilogen.